Table of Contents
<< Previous Issue | Feb 2019 (Vol: 2019, Issue: 2) | Next Issue >> |
- Section: Licensing
-
AbbVie Joins BCMA Race with Tenebio in a US$90 M Upfront Deal
- Section: Research & Development
-
Neurocrine Adds Four Gene Therapies to Pipeline with Voyager Collaboration
-
GSK Hopes to Lead New Class of Immunotherapies with Merck KGaA Collaboration
-
Janssen to Focus on Retinal Diseases with Multi-part MeiraGTx Deal
-
Xencor Collaborates with Genentech for Novel Interleukin-15 Bispecific Antibodies
-
Alexion Pharmaceuticals Takes on Amyloidosis with Caelum Biosciences